Albireo Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
22 August 2022 - 11:13PM
Albireo Pharma, Inc. (Nasdaq: ALBO), a rare liver disease company
developing novel bile acid modulators, today announced the grant of
inducement restricted stock units to acquire 17,300 shares of
Albireo’s common stock. The restricted stock units were granted as
an inducement material to the employee’s acceptance of employment
with Albireo in accordance with Nasdaq Listing Rule 5635(c)(4). The
restricted stock units vest over a four-year period, subject to the
employee’s continued service with Albireo through the applicable
vesting dates. The vesting schedule for each restricted stock unit
is 25 percent on the one-year anniversary of the employee’s start
date with Albireo and 75 percent in 12 equal quarterly installments
thereafter. The restricted stock units are subject to the terms and
conditions of Albireo’s 2020 Inducement Equity Incentive Plan.
About Albireo
Albireo Pharma is a rare disease company focused on the
development of novel bile acid modulators to treat rare pediatric
and adult liver diseases. Albireo’s lead product, Bylvay, was
approved by the U.S. FDA as the first drug for the treatment of
pruritus in all types of progressive familial intrahepatic
cholestasis (PFIC), and in Europe, Bylvay has been approved
for the treatment of PFIC. Bylvay is also being developed to treat
other rare pediatric cholestatic liver diseases with global Phase 3
trials in Alagille syndrome (ALGS) and biliary atresia, as well as
Open-label Extension (OLE) studies for PFIC and ALGS. The Company
has also completed a Phase 1 clinical trial for A3907 to advance
development in adult cholestatic liver disease, with IND-enabling
studies progressing with A2342 for viral and cholestatic liver
disease. Albireo was spun out from AstraZeneca in 2008 and is
headquartered in Boston, Massachusetts, with its key operating
subsidiary in Gothenburg, Sweden. For more information on Albireo,
please visit www.albireopharma.com.
Media Contact:Colleen Alabiso,
857-356-3905, colleen.alabiso@albireopharma.comLance Buckley,
917-439-2241, lbuckley@lippetaylor.com
Investor Contact:Hans Vitzthum, LifeSci
Advisors, LLC., 617-430-7578
Albireo Pharma (NASDAQ:ALBO)
Historical Stock Chart
Von Feb 2024 bis Mär 2024
Albireo Pharma (NASDAQ:ALBO)
Historical Stock Chart
Von Mär 2023 bis Mär 2024